BC ECHO on Substance Use – Opioid Use Disorder: Cycle 3, Session 8
Transitioning between pharmacotherapies for opioid use disorder (SROM focus)
Tuesday November 17, 12:00-1:00 PM PDT
Presenter: Dr. Ramm Hering, Medical Director, Addiction Medicine, Island Health; Physician Lead, Addiction Medicine Consult Service (AMCS), Royal Jubilee and Victoria General Hospitals, Island Health; Victoria Site Director, BC Centre on Substance Use Addiction Medicine Fellowship; Clinical Instructor, Faculty of Medicine, UBC
At the end of this session, you should be able to:
- Understand the evidence to support slow release oral morphine (SROM) as a 3rd line treatment option for opioid use disorder.
- Evaluate a patient for SROM.
- Safely and effectively transition a patient between different pharmacotherapies for opioid use disorder, specifically from first and second line treatment options (i.e., buprenorphine/naloxone, methadone) to SROM, in cases where these medications have not been beneficial.
- Safely initiate and titrate SROM.
- Evaluate treatment plans with SROM.
- Determine which office-based and laboratory tests (e.g., urine drug testing) are clinically useful and appropriate during transitions between pharmacotherapies (i.e., from methadone to buprenorphine/naloxone) and when to use them.